Dan Staner appointed as Vice President and
Managing Director, Switzerland
Reinforces Moderna’s commitment to Europe
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines to create a new
generation of transformative medicines for patients, today
announced the appointment of Dan Staner as Vice President and
General Manager, Switzerland, effective today. Switzerland is the
first country outside of North America to host a Moderna regional
hub and commercial organization.
Mr. Staner is responsible for Moderna’s presence and activities
in Switzerland, building a team to cover a range of functions –
medical, regulatory, pricing, reimbursement, market access,
government affairs and commercial operations – for the Swiss
market. As Moderna builds its European footprint, Mr. Staner will
work in close collaboration with Mr. Nicolas Chornet who was
recently appointed as SVP International Manufacturing, Europe,
based in Basel.
Recently, the Swiss Federal Government concluded an agreement
with the Company for the procurement of 4.5 million vaccine doses
of mRNA-1273, its investigational vaccine against COVID-19. In May
2020, Moderna and Lonza, a Swiss-based company, also announced a
strategic collaboration to enable larger scale global manufacture
by Lonza of mRNA-1273 and additional Moderna products in the
future.
“I am first and foremost honored to have joined Moderna. I am
very excited to have the responsibility for building Moderna’s
first commercial organization outside of North America,” said Mr.
Staner. “I look forward to working with Switzerland’s healthcare
stakeholders as we face the immediate challenge of COVID-19. This
is a wonderful opportunity for Switzerland to continue its leading
role in innovation and biopharmaceuticals for the benefit of
society globally.”
“Switzerland is a leader in life-sciences, with a dynamic pool
of industry talent, scientists, research organizations, investors
and global health policymakers,” said Stéphane Bancel, CEO of
Moderna. “Since Moderna’s founding, Switzerland has played an
important role in Moderna’s development thanks to the long-term
support of our Swiss investors and their business advice. Opening
our first subsidiary outside North America in Switzerland is a
natural step for Moderna. I am pleased to welcome Dan Staner to the
Moderna team. I had the chance to work with Dan at Lilly and I know
that he has a proven track record in building and leading global
biopharmaceutical commercial teams in Switzerland and around the
world.”
Mr. Staner brings over 25 years of experience in the global
pharmaceutical industry, principally with Eli Lilly. His previous
leadership roles have included finance, marketing, strategy, global
product development. and general management. His geographic
responsibilities at different times covered Switzerland, Europe,
USA, Middle East, Africa, and South Asia. He is a Swiss national
and holds an MSc in Economics and Business Management from H.E.C.
University of Lausanne.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that can have a therapeutic or
preventive benefit and have the potential to address a broad
spectrum of diseases. The company’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing Moderna the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases and cardiovascular diseases,
independently and with strategic collaborators.
Headquartered in Cambridge, Mass., with a European headquarters
in Basel, Switzerland, Moderna currently has strategic alliances
for development programs with AstraZeneca PLC and Merck & Co.,
Inc., as well as the Defense Advanced Research Projects Agency
(DARPA), an agency of the U.S. Department of Defense, and the
Biomedical Advanced Research and Development Authority (BARDA), a
division of the Office of the Assistant Secretary for Preparedness
and Response (ASPR) within the U.S. Department of Health and Human
Services (HHS). Moderna has been named a top biopharmaceutical
employer by Science for the past five years. To learn more, visit
www.modernatx.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding the Company’s development of
a potential vaccine against the novel coronavirus, the potential
for mRNA-1273 to prevent COVID-19 disease and slow the spread of
SARS-CoV-2, the Company’s international expansion and staffing
efforts, and plans to increase and scale production of mRNA-based
medicines. In some cases, forward-looking statements can be
identified by terminology such as “will,” “may,” “should,” “could”,
“expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,”
“estimates,” “predicts,” “potential,” “continue,” or the negative
of these terms or other comparable terminology, although not all
forward-looking statements contain these words. The forward-looking
statements in this press release are neither promises nor
guarantees, and you should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties, and other factors, many of which are beyond
Moderna’s control and which could cause actual results to differ
materially from those expressed or implied by these forward-looking
statements. These risks, uncertainties, and other factors include,
among others: the fact that there has never been a commercial
product utilizing mRNA technology approved for use; the fact that
the rapid response technology in use by Moderna is still being
developed and implemented; the fact that the safety and efficacy of
mRNA-1273 has not yet been established; potential adverse impacts
due to the global COVID-19 pandemic such as delays in regulatory
review, manufacturing and clinical trials, supply chain
interruptions, adverse effects on healthcare systems and disruption
of the global economy; and those other risks and uncertainties
described under the heading “Risk Factors” in Moderna’s most recent
Quarterly Report on Form 10-Q filed with the U.S. Securities and
Exchange Commission (SEC) and in subsequent filings made by Moderna
with the SEC, which are available on the SEC’s website at
www.sec.gov. Except as required by law, Moderna disclaims any
intention or responsibility for updating or revising any
forward-looking statements contained in this press release in the
event of new information, future developments or otherwise. These
forward-looking statements are based on Moderna’s current
expectations and speak only as of the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200916005315/en/
Moderna Contacts Media: Colleen Hussey Senior Manager,
Corporate Communications 617-335-1374
Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Swiss Media Contacts Nick Miles & Toomas Kull (FR/EN)
Michael Füglister (DE) Cabinet Privé de Conseils, Geneva
moderna@cpc-pr.com +41 22 552 46 46
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024